ITBMed
OverviewSuggest Edit
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
| Type | Private | |
| HQ | Stockholm, SE | Map |
| Website | itb-med.com |
Locations
Latest Updates
| Cybersecurity rating | A | More |
Key People/Management at ITBMed
Pablo Legorreta
Jan Ståhlberg
David Berglund
Alan Slade
David Sachs
Molly Chiaramonte
ITBMed Office Locations
ITBMed Financials and Metrics
Summary Metrics
ITBMed total Funding | $67 m |
ITBMed latest funding size | $67 m |
Time since last funding | 3 years ago |
ITBMed investors | Pablo Legoretta |
ITBMed Cybersecurity Score
ITBMed Online and Social Media Presence
ITBMed's Trends
ITBMed Frequently Asked Questions
Who are ITBMed key executives?
ITBMed's key executives are Pablo Legorreta, Jan Ståhlberg and David Berglund.
Who are ITBMed competitors?
Competitors of ITBMed include Cantabio Pharmaceuticals, Novartis and Rigel Pharmaceuticals.
Where is ITBMed headquarters?
ITBMed headquarters is located at Sonja Kovalevskys Gata 4, Stockholm.
Where are ITBMed offices?
ITBMed has offices in Stockholm and New York.
How many offices does ITBMed have?
ITBMed has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies